16 June 2014 | News | By BioSpectrum Bureau
Neridronic acid is the only approved therapeutic drug for osteogenesis till date
Singapore: Italian based Abiogen Pharma signed an agreement with Lee's Pharmaceutical Holdings of Hong Kong, securing license for distribution and supply of neridronic acid in mainland China, Hong Kong, Macau and Taiwan.
As per the agreement, Lee pharmaceuticals is licensed to register, import, market, distribute and sell drugs to treat rare disorders like osteogenesis imperfecta and complex regional pain syndrome.
Neridronic acid is the only approved therapeutic drug available to treat these serious diseases. Osteogenesis imperfecta or the brittle bone disease causes deformities with results in abnormal growth and destruction. The drug has proved its safety profile on administration, over the years and has no side effects even in neonates and older population.
Dr Massimo Di Martino, president and CEO of Abiogen Pharma appreciated this as a great opportunity for people in China and neighboring regions, to get rid of critical diseases for which no other medication was currently available.
Lee Pharmaceuticals CEO Dr Benjamin Li said, "This demonstrated the company's commitment towards curing rare diseases as this was the fourth orphan drug, introduced by Lee pharma to treat diseases that have otherwise no known treatment options."